Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan Syndrome
Abstract
Aortic aneurysm and dissection are manifestations of Marfan syndrome (MFS), a disorder caused by mutations in the gene that encodes fibrillin-1. Selected manifestations of MFS reflect excessive signaling by the transforming growth factor–β (TGF-β) family of cytokines. We show that aortic aneurysm in a mouse model of MFS is associated with increased TGF-β signaling and can be prevented by TGF-β antagonists such as TGF-β–neutralizing antibody or the angiotensin II type 1 receptor (AT1) blocker, losartan. AT1 antagonism also partially reversed noncardiovascular manifestations of MFS, including impaired alveolar septation. These data suggest that losartan, a drug already in clinical use for hypertension, merits investigation as a therapeutic strategy for patients with MFS and has the potential to prevent the major life-threatening manifestation of this disorder.
Footnotes
Supporting Online Material www.sciencemag.org/cgi/content/full/312/5770/117/DC1 Materials and Methods Figs. S1 to S4 References
References and Notes
References
- 1. Dietz HC, et al Nature. 1991;352:337.[PubMed][Google Scholar]
- 2. Sakai LY, Keene DR, Glanville RW, Bachinger HP. J. Biol. Chem. 1991;266:14763.[PubMed]
- 3. Visconti RP, Barth JL, Keeley FW, Little CD. Matrix Biol. 2003;22:109.[PubMed]
- 4. Isogai Z, et al J. Biol. Chem. 2003;278:2750.[PubMed][Google Scholar]
- 5. Neptune ER, et al Nat. Genet. 2003;33:407.[PubMed][Google Scholar]
- 6. Ng CM, et al J. Clin. Invest. 2004;114:1586.[Google Scholar]
- 7. Judge DP, et al J. Clin. Invest. 2004;114:172.[Google Scholar]
- 8. Jones KB, et al Spine. 2005;30:291.[PubMed][Google Scholar]
- 9. Rossi P, et al Cell. 1988;52:405.[PubMed][Google Scholar]
- 10. Schlumberger W, Thie M, Rauterberg J, Robenek H. Arterioscler. Thromb. 1991;11:1660.[PubMed]
- 11. Heldin CH, Miyazono K, ten Dijke P. Nature. 1997;390:465.[PubMed]
- 12. Loeys BL, et al Nat. Genet. 2005;37:275.[PubMed][Google Scholar]
- 13. Gott VL, et al N. Engl. J. Med. 1999;340:1307.[PubMed][Google Scholar]
- 14. Lavoie P, et al J. Hypertens. 2005;23:1895.[PubMed][Google Scholar]
- 15. Lim DS, et al Circulation. 2001;103:789.[Google Scholar]
- 16. Shores J, Berger KR, Murphy EA, Pyeritz RE. N. Engl. J. Med. 1994;330:1335.[PubMed]
- 17. Spence SG, et al Teratology. 1995;51:367.[PubMed][Google Scholar]
- 18. Everett AD, Tufro-McReddie A, Fisher A, Gomez RA. Hypertension. 1994;23:587.[PubMed]
- 19. Wolf G, Ziyadeh FN, Stahl RA. J. Mol. Med. 1999;77:556.[PubMed]
- 20. Fukuda N, et al Am. J. Hypertens. 2000;13:191.[PubMed][Google Scholar]
- 21. Naito T, et al Am. J. Physiol. Renal Physiol. 2004;286:F278.[PubMed][Google Scholar]
- 22. Nabel EG, et al Proc. Natl. Acad. Sci. U.S.A. 1993;90:10759.[Google Scholar]
- 23. Gadson PF, Jr., et al Exp. Cell Res. 1997;230:169.[PubMed][Google Scholar]
- 24. Topouzis S, Majesky MW. Dev. Biol. 1996;178:430.[PubMed]
- 25. Nollen GJ, et al Heart. 2002;87:470.[Google Scholar]
- 26. Jones ES, Black MJ, Widdop RE. J. Mol. Cell. Cardiol. 2004;37:1023.[PubMed]
- 27. Daugherty A, Manning MW, Cassis LA. Br. J. Pharmacol. 2001;134:865.
- 28. Nagashima H, et al Circulation. 2001;104:I282.[PubMed][Google Scholar]
- 29. Suzuki J, et al Circulation. 2002;106:847.[PubMed][Google Scholar]
- 30. Rodriguez-Vita J, et al Circulation. 2005;111:2509.[PubMed][Google Scholar]
- 31. Coucke PJ, et al Nat. Genet. in press. [PubMed]
- 32. We thank K. Khan for expert technical assistance. Supported by the NIH (H.C.D., D.P.J., D.L.H., D.B.R., F.R.), the Smilow Center for Marfan Syndrome Research (H.C.D.), the National Marfan Foundation (H.C.D., D.P.J.), the Howard Hughes Medical Institute (H.C.D.), the Victor A. McKusick Endowment (H.C.D.), and the Dana and Albert “Cubby” Broccoli Center for Aortic Diseases (D.P.J.). All protocols for mouse treatment were approved by the Animal Care and Use Committee of the Johns Hopkins University School of Medicine.